ARF1 and Familial prostate cancer: To study the role of ARF1 in ERK1/2 activation by OR51E2 in prostate cancer cells, we determined the effect of CRISPR-Cas9-mediated KO of ARF1 via transient expression of CRISPR-Cas9 KO plasmids targeting ARF1 as described previously (Khater et al., 2021a) and specific pharmacological inhibition of ARF1 guanine nucleotide exchange factors (GEFs) at either the GA or the PM.